AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

ARGX · NASDAQ · Biotechnology

argenx (ADR) (ARGX)

Develops antibody medicines for severe autoimmune diseases around the VYVGART franchise.

$941.32

vs last close−22.47 (−2.33%)

In millions of USD, except per-share figures

In millions	Q1 FY23Mar 2023	Q2 FY23Jun 2023	Q3 FY23Sep 2023	Q4 FY23Sep 2023	Q2 FY24Mar 2024	Q1 FY24Mar 2024	Q3 FY24Sep 2024	Q4 FY24Sep 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q4 FY25Dec 2025	Q2 FY26Jun 2026
Revenue	−258	468	330	330	401	401	573	573	791	948	3,206	2,816
Cost of revenue	−808	370	36	36	43	43	59	59	81	111	340	279
Gross profit	550	107	294	294	358	358	514	514	710	837	2,866	2,536
	507	287	374	374	451	451	500	500	569	633	2,015	1,690
Research & development	−115	331	192	192	225	225	236	236	309	328	443	486
	−131	285	192	192	236	236	278	278	276	321	355	773
Selling & marketing	202	0	0	0	0	0	0	0	0	0	0	240
General & administrative	507	0	0	0	0	0	0	0	0	0	0	533
Other expenses	752	−359	−9	−9	−10	−10	−14	−14	−17	−16	1,217	431
Operating income	43	−189	−81	−81	−93	−93	14	14	141	204	851	847
	14	46	−3	−3	19	19	74	74	61	83	141	112
Interest income	3	37	30	30	39	39	41	41	37	38	44	92
Interest expense	0	0	0	0	1	1	1	1	1	1	1	2
Other non-operating income	−120	−2	2	2	−20	−20	−75	−75	−62	−84	−144	0
Income before tax	56	−147	−83	−83	−74	−74	88	88	202	287	992	959
Income tax expense	10	−34	−11	−11	−13	−13	−3	−3	33	42	−55	119
Net income from continuing operations	46	−113	−73	−73	−62	−62	91	91	169	245	1,047	840
Other adjustments	0	0	0	0	0	0	0	0	0	0	0	−1
Net income	46	−113	−73	−73	−62	−62	91	91	169	245	1,047	839
EPS, basic	$0.77	−$2.03	−$1.25	−$1.25	−$1.04	−$1.04	$1.52	$1.52	$2.78	$6.85	$14.25	$13.49
EPS, diluted	$0.77	−$2.03	−$1.25	−$1.25	−$1.04	−$1.04	$1.39	$1.39	$2.58	$6.37	$13.22	$13.02
Weighted average shares, basic	56	56	58	58	59	59	60	60	61	61	61	62
Weighted average shares, diluted	56	56	58	58	59	59	66	66	66	66	66	64
EBITDA	156	−183	−83	−83	−74	−74	89	89	203	288	1,009	864
Depreciation & amortization	16	4	0	0	0	0	0	0	0	0	15	17
EBIT	163	−187	−83	−83	−74	−74	89	89	203	288	995	847